Research Article Details
| Article ID: | A07598 |
| PMID: | 32429653 |
| Source: | Pol J Pathol |
| Title: | Role of mast cells in the pathogenesis of liver fibrosis in nonalcoholic fatty liver disease. |
| Abstract: | Nonalcoholic fatty liver disease (NAFLD), a very common comorbidity of obesity, may progress from simple steatosis to nonalcoholic steatohepatitis and liver cirrhosis. The aim of this study was to determine whether mast cells (MCs) participate in the pathogenesis of liver fibrosis in patients with NAFLD. Liver specimens collected either from obese subjects or the control group were prepared for histological examination. The patients were divided into groups depending on inflammation and fibrosis grade, and the mean total number of mast cells/mm2 and those located only in portal areas/ fibrous septa or within lobules were calculated for each grade. Mast cells were detected by pina-cyanol erythrosinate staining. There was a strong positive correlation between the number of mast cells, especially those located within portal areas and fibrous septa, and the liver fibrosis grade (r = 0.736, p < 0.0001). No similar dependency between the number of mastocytes within lobules and liver fibrosis grade was identified. The results from this study suggest the involvement of mast cells from portal areas and fibrous septa in the pathogenesis of liver fibrosis in patients with NAFLD. |
| DOI: | 10.5114/pjp.2020.95414 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |